$3.9981
0.0581[1.47%]
At close: Apr 24
$3.9981
0[0.00%]
PreMarket: 6:31PM EDT
Aldeyra Therapeutics
(NASDAQ:ALDX)Latest News for Aldeyra Therapeutics Stock (NASDAQ:ALDX)
Aldeyra Therapeutics Stock (NASDAQ: ALDX)
Categories: All
Thursday, April 04, 2024
Wednesday, April 03, 2024
- Aldeyra Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.Benzinga Newsdesk - Apr 3, 2024, 12:02PM
- Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price TargetBenzinga Newsdesk - Apr 3, 2024, 9:58AM
Tuesday, April 02, 2024
Thursday, March 28, 2024
- Aldeyra Therapeutics shares are trading higher. The company announced the clinical development plan intended to enable resubmission of a New Drug Application for reproxalap in dry eye disease.Benzinga Newsdesk - Mar 28, 2024, 12:02PM
- Aldeyra Therapeutics Disclosed Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap In Dry Eye DiseaseBenzinga Newsdesk - Mar 28, 2024, 7:14AM
Tuesday, March 05, 2024
Thursday, January 04, 2024
Thursday, December 21, 2023
Tuesday, December 19, 2023
- Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis StudyVandana Singh - Dec 19, 2023, 1:56PM
- Market-Moving News for December 19thBenzinga Newsdesk - Dec 19, 2023, 8:33AM
- Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial AssessmentsBenzinga Newsdesk - Dec 19, 2023, 7:06AM
Tuesday, November 28, 2023
Monday, November 27, 2023
- Aldeyra Therapeutics Shares To Resume Trade At 4:35 p.m. ETBenzinga Newsdesk - Nov 27, 2023, 4:13PM
- Aldeyra Therapeutics Receives Complete Response Letter From FDA; Says Additional Trial Required To Demonstrate Positive Effect On The Treatment Of Ocular Symptoms In Dry Eye DiseaseBenzinga Newsdesk - Nov 27, 2023, 4:08PM
Wednesday, November 01, 2023
- Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Nov 1, 2023, 1:59PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Nov 1, 2023, 1:31PM
- What's Going On With Aldeyra Therapeutics Stock?Erica Kollmann - Nov 1, 2023, 11:52AM
- Aldeyra Will Receive A Option Fee Of $1M And Upfront Payment Of $100M Less Option Fees If AbbVie Chooses To Exercise; Would Be Eligible To Receive Up To $300M In Regulatory And Commercial Milestone Payments, Inclusive Of A $100M Paymeent Upon FDA ApprovalBenzinga Newsdesk - Nov 1, 2023, 10:54AM
- Aldeyra Therapeutics shares are trading higher after the company announced that it entered into an exclusive options agreement with AbbVie.Benzinga Newsdesk - Nov 1, 2023, 10:51AM
- Reported Earlier, Aldeyra Therapeutics Enters Into Exclusive Option Agreement With AbbVie For License To Develop And Commercialize ReproxalapBenzinga Newsdesk - Nov 1, 2023, 10:51AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Nov 1, 2023, 9:06AM
- Market-Moving news for November 1stBenzinga Newsdesk - Nov 1, 2023, 8:45AM
Thursday, October 19, 2023
Tuesday, October 17, 2023
- Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $8Benzinga Newsdesk - Oct 17, 2023, 11:24AM
- Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023Benzinga Insights - Oct 17, 2023, 11:00AM
- Oppenheimer Downgrades Aldeyra Therapeutics to PerformBenzinga Newsdesk - Oct 17, 2023, 4:18AM
Monday, October 16, 2023
- Crude Oil Moves Lower; Consolidated Communications Shares JumpLisa Levin - Oct 16, 2023, 2:30PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Oct 16, 2023, 1:31PM
- Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Oct 16, 2023, 1:09PM
- Nasdaq Gains 1%; Charles Schwab Earnings Top ViewsLisa Levin - Oct 16, 2023, 12:08PM
- Dow Surges Over 200 Points; Empire State Manufacturing Index Falls In OctoberLisa Levin - Oct 16, 2023, 10:07AM
- Aldeyra Therapeutics Shares Resumed Trade Then Again Halted On Circuit Breaker, This Time To The Downside, Stock Now Down -57.6%Benzinga Newsdesk - Oct 16, 2023, 10:06AM
- Aldeyra Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Down -55.1%Benzinga Newsdesk - Oct 16, 2023, 10:00AM
- Aldeyra Therapeutics Shares Resume TradeBenzinga Newsdesk - Oct 16, 2023, 9:44AM
- Aldeyra Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Down -66.5%Benzinga Newsdesk - Oct 16, 2023, 9:42AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Oct 16, 2023, 9:05AM
- Why Aldeyra Therapeutics (ALDX) Stock Is Getting ObliteratedHenry Khederian - Oct 16, 2023, 8:49AM
- Aldeyra Therapeutics shares are trading lower after the FDA said it identified substantive review issues in connection with the NDA for reproxalap.Benzinga Newsdesk - Oct 16, 2023, 8:49AM
- Aldeyra Therapeutics Says That The FDA Stated That Reproxalap For Signs And Symptoms Of Dry Eye Disease Does Not Appear To Have Data To Support The Clinical Relevance Of The Ocular Signs To Support The Dry Eye Indication - 8KBenzinga Newsdesk - Oct 16, 2023, 8:11AM